UK-Switzerland FTA Boosts Life Sciences Opportunities

Check out our latest article by our CFO, Tony Proctor. China’s biotech surge is reshaping the global life‑sciences landscape — a must-read analysis from our CFO on what this means for innovation, investment, and clinical development: https://lnkd.in/dFjERdRW Read, share, and tell us: how will your organization adapt? #Biotech #China #LifeSciences #ClinicalTrials #Pharma #HealthcareInnovation #BiotechInvestment #GlobalHealth #CFOInsights #DrugDevelopment

SFBN Feed: Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most https://lnkd.in/gM282BXc I spent nearly two decades covering the biotech and pharma sector, first in Washington, D.C., and then in Beijing. My first story, published in 2007, covered the U.S. Food and Drug Administration’s decision to open its inaugural overseas office in China, a fast-emerging market I later covered for 12 years. In that time, I saw a lot of discussion about what the growth of China’s biotech sector would mean for the U.S. Never have I been more concerned about that discourse than I am now. In recent years, China has become a biotech innovator, accounting for 34% of roughly 14,088 new drugs in global clinical development, leading the United States’ 27%. China is now contributing to 40% of new drugs entering clinical stage each year, according to data provider Pharmcube . The company also noted that China’s out-licensing deals rose nearly tenfold from 2021 to 2025, to an record… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

Europe has never had a problem producing great science. The challenge has often been turning that science into global biotech success stories. That's why the proposed EU Biotech Act has caught my attention. The goal is straightforward: make it easier and faster for biotech companies to innovate, run clinical trials, scale manufacturing, and attract investment within Europe. If it delivers on those ambitions, it could help keep more breakthrough innovations, talent, and capital in the region rather than seeing them move elsewhere. For an industry where speed matters and funding is competitive, reducing complexity can make a real difference. It'll be interesting to see how the final legislation develops over the coming months and whether it can give European biotech the boost many in the industry have been calling for. What's your view? Could the EU Biotech Act be a turning point for Europe's biotech sector? #Iqvia #Iqviabiotech #Biotech #LifeSciences #HealthcareInnovation #Pharma #ClinicalTrials #Biotechnology #EuropeanInnovation #EUBiotechAct

Australia's biotech sector just grew 43% in two years. That's not a blip. That's a structural shift. More companies are moving programs out of discovery and into development than ever before — and the bottleneck isn't the science. It's everything that comes after it. CMC. Manufacturing. DMPK. Formulation. Regulatory alignment. The stuff that doesn't make the press release but decides whether your asset reaches the clinic on time — or doesn't. The companies winning this stage aren't the ones with the best molecules. They're the ones who integrated their development functions early enough to actually move. That's where the gap is. And it's widening. At Fenix, we work with APAC biotech companies to close it — connecting them into end-to-end development capabilities so the transition from discovery to clinic doesn't become the place momentum goes to die. The opportunity in Australian biotech is real. The question is whether your development infrastructure is ready to meet it. #biotech #Australia #lifesciences #drugdevelopment #APAC #CMC

How should the US respond to China's growing strength in biotech? Representative John Moolenaar, who chairs the House Select Committee on China, has introduced legislation that would restrict US investment in Chinese biotech companies. This shows the debate has moved from industry conferences into an actual policy proposal in Congress. Part of what is driving this debate is how large China's share of global biopharma deal making has become. One estimate puts Chinese assets at more than two thirds of total industry deal value in 2026, up from 42% the prior year and 5% five years earlier. Even without confirming the exact numbers, the direction described matches what many licensing announcements already show. Chinese developed drugs have gone from a small share of pharma pipelines to a central one in a few years. If this legislation moves forward, it could also affect how easily Chinese developed drugs enter clinical trials in the United States, since fewer licensing deals would mean fewer of those drugs reaching US patients through trials at all. #biotech #pharma #clinicaltrials

Europe once produced half the world's new medicines. Today it's 20 percent - and falling. Stefan Oelrich dissects why the biotech race is being run in Boston, Shenzhen and Cambridge, while Europe still debates the rulebook. His verdict: the lighthouse is within reach - but only if Europe stops writing incremental policy for a revolutionary moment. https://lnkd.in/djM7xaqn #Biotech #Pharma #EuropeanCompetitiveness #HealthcareInnovation #LifeSciences #GeneAndCellTherapy #IndustrialPolicy #InnovationEcosystems #GlobalHealth #StrategicSovereignty #TheSternStewartInstitute

I was honored to join the Biotech CEO Forum this week for a thoughtful discussion on engaging China in global drug development.   My key message: China can offer important opportunities in patient access, clinical development capacity, innovation, and partnering, but the value depends on whether China-generated data are designed to support global regulatory and business decisions.   For many biotech companies with limited resources, regional development is often necessary. The goal is not to make every study global from day one, but to ensure early regional studies remain useful for future FDA/EMA discussions, partnering, financing, or M&A.   China development should not be viewed as a shortcut. It should be part of a globally planned evidence-generation and value-creation strategy. When planned thoughtfully, a regional strategy can become a significant step toward long-term, global opportunity.    Thank you to the organizers and participating CEOs for the engaging discussion. Liang Schweizer Jodie Morrison #Biotech #DrugDevelopment #RegulatoryStrategy #FDA #ChinaBiotech #GlobalDevelopment

Why are more biotech and pharma companies choosing Australia for early phase clinical trials? ✅ Rapid study start-up ✅ Generous R&D tax incentives ✅ World-class investigators and research sites ✅ Data accepted by major global regulators Partner with Emerald Clinical Trials to maximize the Australian advantage and accelerate critical development milestones.- https://bit.ly/4blxPpD #ClinicalResearch #Australia #EarlyPhase #Biotech #DrugDevelopment #EmeraldClinicalTrials

Chinese biopharma is becoming increasingly global — but the next bottleneck may not be science. A recent Reuters report highlighted the shortage of talent with hands-on experience in global clinical development, regulatory strategy and cross-cultural execution. Strong assets open the door. A clear global strategy — and an organization people trust — determine how far they can go. #Biopharma #ClinicalDevelopment #GlobalTalent